<DOC>
	<DOCNO>NCT02476552</DOCNO>
	<brief_summary>This open-label study 2 part , plus extension study follow completion Parts 1 2 , conduct approximately 12 subject ( 6 subject Part 1 ; 6 subject Part 2 ) cancer examine absorption , metabolism , excretion , absolute bioavailability niraparib .</brief_summary>
	<brief_title>Absorption , Metabolism , Excretion , Determination Absolute Bioavailability Niraparib Subjects With Cancer</brief_title>
	<detailed_description>Part 1 : After overnight fast least 10 hour , subject receive single , oral dose niraparib ( unlabeled active pharmaceutical ingredient ) Day 1 . Two hour oral dose , subject receive 15-minute IV infusion niraparib ( labeled pharmaceutical ingredient ) . Part 2 : After overnight fast least 10 hour , subject receive single , oral dose niraparib , label active pharmaceutical ingredient .</detailed_description>
	<mesh_term>Niraparib</mesh_term>
	<criteria>Subject , male female , least 18 year age . Subject histologically cytologically confirm diagnosis metastatic locally advanced solid tumor fail respond standard therapy , progress despite standard therapy , refuse standard therapy , standard therapy exists , may benefit treatment poly ( adenosine diphosphate [ ADP ] ribose ) polymerase ( PARP ) inhibitor . The diagnosis must confirm previous compute tomography ( CT ) scan . The subject adequate organ function : Subject must ECOG performance status 0 2 . Female subject childbearing potential must negative serum pregnancy test ( beta human chorionic gonadotropin [ hCG ] ) within 72 hour prior receive first dose study drug . Subject undergone palliative radiotherapy within 1 week study drug administration , encompass &gt; 20 % bone marrow . Subject persistent &gt; Grade 2 toxicity prior cancer therapy . Subject know hypersensitivity component niraparib . Subject major surgery within 3 week study drug administration recover effect major surgery . Subject consider medical risk due serious , uncontrolled medical disorder ; nonmalignant systemic disease ; active , uncontrolled infection . Examples include , limited , uncontrolled ventricular arrhythmia , recent ( within 90 day Screening Visit ) myocardial infarction , uncontrolled major seizure disorder , unstable spinal cord compression , superior vena cava syndrome , psychiatric disorder prohibits obtain informed consent . Subject participate radioactive clinical study receive investigational radiolabeled drug within 6 month prior study drug administration ( subject participate Part 2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>